A Phase 4 interventional study of Intervention 1: Adrenalectomy and Intervention 2: Semaglutide in Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) and Subclinical Cushing's, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Texas Southwestern Medical Center · Phase 4, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with mild autonomous cortisol secretion (MACS). The study will also learn how these treatments impact body composition, blood pressure, cholesterol, inflammation, muscle strength, and quality of life.
The main questions the study aims to answer are:
Participants will:
This single-center, prospective, interventional study evaluates metabolic responses to surgical versus medical treatment in adults with mild autonomous cortisol secretion (MACS). The study includes:
The primary objective is to compare changes in insulin sensitivity measured by hyperinsulinemic-euglycemic clamp (M-value) from baseline to week 26. Secondary outcomes include cortisol dynamics, steroid profiling, cardiometabolic biomarkers, body composition, blood pressure, muscle strength, and patient-reported quality of life.
Semaglutide is administered within its FDA-approved indication for weight management; adrenalectomy is standard of care. No IND is required.
Participants who complete the initial 26-week study period and meet applicable eligibility criteria may elect to participate in an optional extension phase through approximately Week 52. During the extension phase, participants continue study follow-up and the intervention specified by the protocol, with additional assessments to evaluate longer-term changes in metabolic, hormonal, anthropometric, and cardiometabolic outcomes. Participation in the extension phase is voluntary and is not required for completion of the initial study period. The original primary outcome remains the change in insulin sensitivity from baseline to Week 26; assessments during the extension phase evaluate longer-term treatment effects and durability of response.
27 studies on the registry are indexed under Adrenal incidentaloma; 12 are open to participants now.
Browse Adrenal incidentaloma studies →University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Optional Extension Phase Eligibility:
Participants who complete the Core Study Period may participate in the Optional Extension Phase if they:
For matched controls, the corresponding matched index participant must also elect to participate in the Optional Extension Phase and remain eligible for continued study participation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with mild autonomous cortisol secretion (MACS) who are clinically eligible for adrenalectomy undergo unilateral adrenalectomy as part of standard clinical care. Participants complete protocol-specified metabolic, hormonal, cardiometabolic, body composition, physical function, and patient-reported outcome assessments through Week 26. Eligible participants may elect to participate in the Optional Extension Phase, with continued follow-up and repeat outcome assessments through Month 12.
Procedure: Intervention 1: Adrenalectomy
Adults with MACS receive semaglutide during the initial 26-week treatment period. Eligible participants who elect to participate in the optional extension phase continue semaglutide treatment and protocol-specified follow-up through Month 12.
Drug: Intervention 2: Semaglutide
Matched adults without adrenal tumors receive semaglutide using the same dosing approach as semaglutide-treated participants with MACS. This arm allows comparison of semaglutide responses between individuals with and without MACS. Eligible matched controls may participate in the Optional Extension Phase through Month 12 if their corresponding matched index participant also elects to participate and both remain eligible for continued study participation.
Drug: Intervention 2: Semaglutide
Surgical removal of one adrenal gland performed by an endocrine surgeon following institutional standard-of-care practices. Includes postoperative monitoring for adrenal insufficiency and routine clinical follow-up.
Once-weekly subcutaneous semaglutide administered according to FDA-approved titration for chronic weight management (0.25 mg to 2.4 mg weekly as tolerated). Participants receive training on injection technique, dose escalation, and safety monitoring.
Change in Insulin Sensitivity (M-value), mg/kg/min
Hyperinsulinemic-euglycemic clamp
Time frame: Baseline to Week 26
Change in fasting plasma glucose, mg/dL
Time frame: Baseline to Week 26; Baseline → Month 12
Change in hemoglobin A1C, %
fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in fasting insulin, µU/mL
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in glucagon, pg/mL
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in c-peptide, nmol/L
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in IGF-1, ng/mL
Fasting blood glucose
Time frame: Baseline to Week 26; Baseline → Month 12
Change in IGF-II, ng/mL
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in IGFBP-1, ng/mL
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in leptin, ng/mL
Fasting blood glucose
Time frame: Baseline to Week 26; Baseline → Month 12
Change in adiponectin, μg/mL
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
% of patients with normal dexamethasone suppression test, %
1-mg dexamethasone suppression test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in steroid profile, ng/24h
25-steroid profiling in the 24-hour urine, reported as aggregate
Time frame: Baseline to Week 26; Baseline → Month 12
Mean change in systolic BP, mmHg
24-hour Ambulatory BP
Time frame: Baseline to Week 26; Baseline → Month 12
Mean change in diastolic BP, mmHg
24-hour Ambulatory BP
Time frame: Baseline to Week 26; Baseline → Month 12
Change in cholesterol, mg/dL
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in Free Fatty Acids, mmol/L
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in C-reactive protein, pg/mL
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in TNF-alpha, pg/mL
Fasting blood glucose
Time frame: Baseline to Week 26; Baseline → Month 12
Change in Interleukin-1, pg/mL
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in Interleukin-6, pg/mL
Fasting blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in body weight, kg
electronic scale
Time frame: Baseline to Week 26; Baseline → Month 12
Change in BMI, kg/m2
calculated from weight and height
Time frame: Baseline to Week 26; Baseline → Month 12
Change in waist circumference, cm
Tape measure
Time frame: Baseline to Week 26; Baseline → Month 12
Change in fat area, cm2
Limited unenhanced CT
Time frame: Baseline to Week 26; Baseline → Month 12
Change in muscle area, cm2
Limited unenhanced CT
Time frame: Baseline to Week 26; Baseline → Month 12
Change in bone mineral density, mg/cm³
Limited unenhanced CT
Time frame: Baseline to Week 26; Baseline → Month 12
Change in chair rise test, stands/30s
Time test, number of stands from chair in 30 seconds
Time frame: Baseline to Week 26; Baseline → Month 12
Change in Hand Grip Strength, kg
Dynamometer
Time frame: Baseline to Week 26; Baseline → Month 12
Change in overall quality of life, score
PROMIS Global Health Questionnaire, domain-specific scales; The Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health v1.2 Questionnaire assesses overall health-related quality of life across multiple domains, including physical health, mental health, social functioning, fatigue, and general well-being. It yields two standardized T-score summary measures (Global Physical Health and Global Mental Health). Score Range: T-scores typically range from 20 to 80. Interpretation: Higher T-scores indicate better health-related quality of life. Assessment Method: Self-report questionnaire; estimated completion time 2-5 minutes.
Time frame: Baseline to Week 26; Baseline → Month 12
Change in disease-specific QoL, score
Cushing Quality of Life Questionnaire (CushingQoL) Description: The Cushing Quality of Life Questionnaire (CushingQoL) is a disease-specific tool assessing health-related quality of life in individuals with hypercortisolism. It contains 12 items scored on a 5-point Likert scale. Score Range: 12 (minimum) to 60 (maximum). Interpretation: Higher scores indicate better quality of life; lower scores indicate poorer quality of life. Domains: Sleep disturbances, mood, physical appearance, social interaction, health concerns. Assessment Method: Self-administered; estimated completion time \~5 minutes.
Time frame: Baseline to Week 26; Baseline → Month 12
Change in mood, score
PROMIS Depression Short Form \& PROMIS Anxiety Short Form Description: The PROMIS Depression Short Form and PROMIS Anxiety Short Form measure depressive and anxiety symptoms over the past seven days, assessing emotional distress, negative affect, and somatic symptoms. Responses are on a 5-point Likert scale ("Never" to "Always"), converted to standardized T-scores. Score Range: T-scores typically range from 20 to 80. Interpretation: Higher scores indicate worse depressive or anxiety symptoms. Assessment Method: Self-report questionnaires; estimated completion time 2-4 minutes each.
Time frame: Baseline to Week 26; Baseline → Month 12
Change in cognition, seconds
Trail Making Test - Part A and Part B (TMT-A and TMT-B) Description: The Trail Making Test Parts A and B assess visual attention, processing speed, cognitive flexibility, and executive function. Part A requires sequential connection of numbers; Part B requires alternating between numbers and letters. Score Range: 0 to 300 seconds (maximum test time). Interpretation: Higher (longer) completion times indicate worse cognitive performance. Assessment Method: Performance-based timed test administered by study personnel; expected duration \~5 minutes.
Time frame: Baseline to Week 26; Baseline → Month 12
Change in sleep, score
PROMIS Sleep Disturbance Short Form Description: The PROMIS Sleep Disturbance Short Form evaluates sleep quality, difficulty initiating and maintaining sleep, and overall sleep problems over the past seven days. Scores are converted into standardized T-scores. Score Range: T-scores typically range from 20 to 80. Interpretation: Higher scores indicate worse sleep disturbance. Assessment Method: Self-administered; estimated completion time 2-4 minutes.
Time frame: Baseline to Week 26; Baseline → Month 12
Change in frailty, score
FRAIL Scale (Fatigue, Resistance, Ambulation, Illnesses, Loss of Weight) Description: The FRAIL Scale is a validated screening instrument assessing functional decline and physiological frailty. It consists of five yes/no items: fatigue, resistance, ambulation, illnesses, and weight loss. Score Range: 0 (minimum) to 5 (maximum). Interpretation: Higher scores indicate greater frailty. Frailty Categories: 0: Robust 1-2: Pre-frail 3-5: Frail Assessment Method: Administered by study personnel; duration \~1 minute.
Time frame: Baseline to Week 26; Baseline → Month 12
Change in eating behavior, score
Eating Behavior and Appetite Questionnaire (EBAQ) Description: The Eating Behavior and Appetite Questionnaire (EBAQ) evaluates hunger, satiety, food cravings, and changes in appetite and eating behavior. It generates domain-specific and total scores. Score Range: Varies by version; treated as continuous scores with defined minimum and maximum values per subscale. Interpretation: Higher scores indicate greater appetite or more pronounced eating-behavior disturbances. Assessment Method: Self-administered; estimated completion time 3-5 minutes.
Time frame: Baseline to Week 26; Baseline → Month 12
Adverse Events and Serious Adverse Events
AEs, SAEs
Time frame: From assigned intervention through 4 weeks after the end of treatment, up to approximately Month 13 for participants entering the Optional Extension Phase.
Change in Insulin Sensitivity (M-value) at Month 12
Hyperinsulinemic-euglycemic clamp
Time frame: Time Frame: Baseline to Month 12
Change in post-DST cortisol as a continuous variable
1-mg dexamethasone suppression test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in ACTH level
Blood test
Time frame: Baseline to Week 26; Baseline → Month 12
DHEA-S
Blood test
Time frame: Baseline to Week 26; Baseline → Month 12
HDL
Blood test
Time frame: Baseline to Week 26; Baseline → Month 12
LDL
Blood test
Time frame: Baseline to Week 26; Baseline → Month 12
triglycerides
Blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Apo B
Blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Lp(a)
Blood test
Time frame: Baseline to Week 26; Baseline → Month 12
HDL function
Blood test
Time frame: Baseline to Week 26; Baseline → Month 12
cholesterol efflux capacity
Blood test
Time frame: Baseline to Week 26; Baseline → Month 12
Change in total fat area
Body composition
Time frame: Baseline to Week 26; Baseline → Month 12
Change in visceral fat area
Body composition
Time frame: Baseline to Week 26; Baseline → Month 12
Change in subcutaneous fat area
Body composition
Time frame: Baseline to Week 26; Baseline → Month 12
Change in muscle area
Body composition
Time frame: Baseline to Week 26; Baseline → Month 12
Change in muscle:fat ratio
Body composition
Time frame: Baseline to Week 26; Baseline → Month 12
Change in liver fat
Body composition
Time frame: Baseline to Week 26; Baseline → Month 12
Change in pancreatic fat
Body composition
Time frame: Baseline to Week 26; Baseline → Month 12
Change in pancreatic volume
Body composition
Time frame: Baseline to Week 26; Baseline → Month 12
Change in adrenal nodule size
CT abdomen
Time frame: Baseline to Week 26; Baseline → Month 12
Plan to share: Yes — De-identified individual participant data (IPD) from the IMPACT-MACS study will be shared in accordance with NIH Data Management and Sharing Policy. Shared IPD will include primary and secondary outcome data such as insulin sensitivity (M-value), hormonal and cardiometabolic biomarkers, body composition measures, ambulatory blood pressure data, physical function tests, patient-reported outcomes, and adverse events. No genetic data will be shared. IPD will become available at the time of primary publication or by the end of the award period, expected by Q2 2030. Data will be accessible to qualified investigators for biomedical research through the NIDDK Central Repository, with requests managed under a Data Use Agreement. IRB approval or exemption is required, and data may not be used for ancestry or non-biomedical research.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Start Date: Individual participant data (IPD) and supporting documents will become available at the time of primary results publication or by the end of the study award period, whichever occurs first. Availability is expected to begin by Q2 2030. End Date: IPD will remain available indefinitely through the NIDDK Central Repository, as long as the repository remains active and able to distribute the data under its Data Use Agreement procedures.
Access criteria: Individual participant data (IPD) and supporting materials will be available to qualified investigators conducting health-related, medical, or biomedical research. Requestors must submit a research proposal and obtain institutional IRB approval or exemption before access is granted. Data will be shared in de-identified form through the NIDDK Central Repository, which manages requests under its governed Data Use Agreement (DUA) process. Approved investigators will be able to access the de-identified IPD, study protocol, and data dictionary through the repository's secure system. No identifiable information or genetic data will be shared.
Data sharing details ↗ · reporter.nih.gov
Started Mar 2026 (actual). Primary completion is estimated for May 2030, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
University of Texas Southwestern Medical Center →